Pacira BioSciences' Receivables - Net rose 14.52% to $115.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $115.3 million, marking a year-over-year increase of 14.52%. This contributed to the annual value of $113.3 million for FY2024, which is 7.34% up from last year.
As of Q3 2025, Pacira BioSciences' Receivables - Net stood at $115.3 million, which was up 0.79% from $114.4 million recorded in Q2 2025.
Pacira BioSciences' 5-year Receivables - Net high stood at $115.3 million for Q3 2025, and its period low was $50.0 million during Q3 2021.
In the last 3 years, Pacira BioSciences' Receivables - Net had a median value of $104.7 million in 2025 and averaged $104.5 million.
Data for Pacira BioSciences' Receivables - Net shows a peak YoY surged of 87.04% (in 2022) over the last 5 years.
Over the past 5 years, Pacira BioSciences' Receivables - Net (Quarterly) stood at $96.3 million in 2021, then increased by 2.16% to $98.4 million in 2022, then increased by 7.28% to $105.6 million in 2023, then increased by 7.34% to $113.3 million in 2024, then rose by 14.52% to $115.3 million in 2025.
Its Receivables - Net was $115.3 million in Q3 2025, compared to $114.4 million in Q2 2025 and $104.7 million in Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value